Back to Search Start Over

Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial

Authors :
Wayne M Sullender, ProfMD
Karen B Fowler, Prof
Vivek Gupta, MD
Anand Krishnan
Debjani Ram Purakayastha
Raghuram Srungaram VLN, PhD
Kathryn E Lafond, MPH
Siddhartha Saha, MD
Francisco S Palomeque, MPH
Paul Gargiullo, PhD
Seema Jain, MD
Renu Lal, PhD
Marc-Alain Widdowson, VetMB
Shobha Broor, ProfMD
Source :
The Lancet Global Health, Vol 7, Iss 7, Pp e940-e950 (2019)
Publication Year :
2019
Publisher :
Elsevier, 2019.

Abstract

Summary: Background: Paediatric vaccination against influenza can result in indirect protection, by reducing transmission to their unvaccinated contacts. We investigated whether influenza vaccination of children would protect them and their household members in a resource-limited setting. Methods: We did a cluster-randomised, blinded, controlled study in three villages in India. Clusters were defined as households (ie, dwellings that shared a courtyard), and children aged 6 months to 10 years were eligible for vaccination as and when they became age-eligible throughout the study. Households were randomly assigned (1:1) by a computer-based system to intramuscular trivalent inactivated influenza vaccine (IIV3) or a control of inactivated poliovirus vaccine (IPV) in the beginning of the study; vaccination occurred once a year for 3 years. The primary efficacy outcome was laboratory-confirmed influenza in a vaccinated child with febrile acute respiratory illness, analysed in the modified intention-to-treat population (ie, children who received at least one dose of vaccine, were under surveillance, and had not an influenza infection within 15 days of last vaccine dose). The secondary outcome for indirect effectiveness (surveillance study) was febrile acute respiratory illness in an unvaccinated household member of a vaccine study participant. Data from each year (year 1: November, 2009, to October, 2010; year 2: October, 2010, to October, 2011; and year 3: October, 2011, to May, 2012) were analysed separately. Safety was analysed among all participants who were vaccinated with at least one dose of the vaccine. This trial is registered with ClinicalTrials.gov, number NCT00934245. Findings: Between Nov 1, 2009, to May 1, 2012, we enrolled 3208 households, of which 1959 had vaccine-eligible children. 1010 households were assigned to IIV3 and 949 households were assigned to IPV. In 3 years, we vaccinated 4345 children (2132 with IIV3 and 2213 with IPV) from 1868 households (968 with IIV3 and 900 with IPV) with 10 813 unvaccinated household contacts. In year 1, influenza virus was detected in 151 (10%) of 1572 IIV3 recipients and 206 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25·6% [95% CI 6·8–40·6]; p=0·010). In year 2, 105 (6%) of 1705 IIV3 recipients and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41·0% [24·1–54·1]; p

Details

Language :
English
ISSN :
2214109X
Volume :
7
Issue :
7
Database :
Directory of Open Access Journals
Journal :
The Lancet Global Health
Publication Type :
Academic Journal
Accession number :
edsdoj.36db867c42304d5490b4847f09075316
Document Type :
article
Full Text :
https://doi.org/10.1016/S2214-109X(19)30079-8